Relatlimab/Nivolumab Shows Clinical Activity in Patients With Heavily Pretreated Advanced Melanoma
Source: Oncology Nursing News, June 2023
Among patients with advanced melanoma with disease progression following treatment with anti–PD-1/L1 therapy, relatlimab plus nivolumab (Opdualag) demonstrated early signs of clinical benefit, according to findings from cohort D of the phase 1/2 RELATIVITY-020 trial (NCT01968109) published in the Journal of Clinical Oncology.
A total of 518 patients with advanced melanoma received nivolumab plus relatlimab were included in this trial. The objective response rate (ORR) was 12.0% (95% CI, 8.8%-15.8%) among patients who had been treated with 1 anti–PD-L1/L1 containing regimen (D1; n = 351). In the cohort of patients who had received at least 1 anti–PD-1/L1 containing regimen (D2; n = 163), the ORR was 9.2% (95% CI, 5.2%-14.7%). Investigators noted that responses appeared most pronounced among patients whose tumors expressed PD-L1 or LAG-3; however, responses were observed regardless of expression.
In D1, the median duration of response (DOR) was not reached (NR; 95% CI, 12.9-NR) and in D2, the median DOR was 12.8 months (95% CI, 6.9-12.9). Moreover, the median progression-free survival (PFS) was 2.1 months (95% CI, 1.9-3.5) in D1 and 3.2 months (95% CI, 1.9-3.6) in D2. The 6-month PFS rates, between D1 and D2, respectively, were 29.1% (95 CI, 24.2%-34.1%) and 27.7% (95% CI, 20.5%-35.4%). The 12-month PFS rates were 21.4% (95% CI, 17.0%-26.1%) vs 16.0% (10.0%-23.0%), respectively.